Search results for "LUCA"

showing 10 items of 359 documents

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation

2021

Sepsis causes high mortality in the setting of septic shock. LEADER and other trials revealed cardioprotective and anti-inflammatory properties of glucagon-like peptide-1 (GLP-1) analogs like liraglutide (Lira). We previously demonstrated improved survival in lipopolysaccharide (LPS)-induced endotoxemia by inhibition of GLP-1 degradation. Here we investigate the effects of Lira in the polymicrobial sepsis model of cecal ligation and puncture (CLP). C57BL/6J mice were intraperitoneally injected with Lira (200 µg/kg/d

0301 basic medicineLipopolysaccharidePhysiologyglucagon-like peptide-1 (GLP-1)Clinical Biochemistryperitoneal and polymicrobial sepsisInflammationRM1-950030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistryArticleendothelial dysfunctionSepsis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineoxidative stressvascular inflammationEndothelial dysfunctionInterleukin 6Molecular Biologyliraglutidebiologybusiness.industrySeptic shockCell Biologybacterial infections and mycosesmedicine.diseasececal ligation and puncture (CLP)Nitric oxide synthase030104 developmental biologychemistrybiology.proteinTherapeutics. Pharmacologymedicine.symptombusinessOxidative stressincretinsAntioxidants
researchProduct

Glucagon-like peptide-1 is associated with poor clinical outcome, lipopolysaccharide translocation and inflammation in patients undergoing cardiac su…

2020

International audience; Introduction: Cardiac surgery with cardiopulmonary bypass (CPB) is associated with gut barrier dysfunction. Gut barrier dysfunction might be estimated non-invasively by lipopolysaccharide (LPS) plasma concentration. Glucagon-like peptide-1 (GLP-1) is a gut secreted hormone that is a potential marker of mucosal integrity. Our objective was to evaluate GLP-1 as a peri-operative marker of gut barrier dysfunction in patients undergoing cardiac surgery with CPB.Methods: GLP-1, intestinal fatty acid binding protein (I-FABP) and lipopolysaccharide were assayed: at induction, after CPB and 24 h after admission in the intensive care unit. The primary end-point was peri-operat…

0301 basic medicineLipopolysaccharidesMaleLipopolysaccharideBiochemistryGastroenterologylaw.inventionchemistry.chemical_compound0302 clinical medicinelawGlucagon-Like Peptide 1Gut barrierImmunology and AllergyProspective StudiesCardiopulmonary Bypassdigestive oral and skin physiologyHematologyCardiac surgeryMiddle AgedCardiopulmonary by passIntensive care unitGlucagon-like peptide-1Digestive translocation3. Good healthCardiac surgeryGlucagon like peptid 1030220 oncology & carcinogenesisFemalemedicine.symptommedicine.medical_specialtyImmunologyInflammationLipopolysaccharide03 medical and health sciencesInternal medicineIntensive caremedicineCardiopulmonary bypassHumansCardiac Surgical ProceduresMolecular BiologyAgedInflammationbusiness.industryEndotoxemia030104 developmental biologychemistrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBiomarkersHormoneCytokine
researchProduct

Whole grain consumption and human health

2020

Whole grains have been associated with a number of health benefits. We systematically reviewed existing meta-analyses of observational studies and evaluated the level of evidence for their putative effects based on pre-selected criteria. Of the 23 included studies, we found convincing evidence of an inverse association between whole grain consumption and risk of type-2 diabetes and colorectal cancer; possible evidence of decreased risk of colon cancer and cardiovascular mortality with increased whole grain intake, as well as increased risk of prostate cancer. Limited or insufficient evidence was available for all other outcomes investigated. Overall findings are encouraging for a positive e…

0301 basic medicineMaleDIETARY FIBERHealth StatusBLOOD-PRESSUREHealth benefitsmeta-analysiHuman healthEating0302 clinical medicinecohort; evidence; fibre; meta-analysis; umbrella review; Whole grainMedicineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateWhole GrainsINSULIN SENSITIVITYcohortWEIGHT-GAINObservational Studies as TopicCardiovascular DiseasesCARDIOVASCULAR-DISEASEMeta-analysisfibreCohortColonic NeoplasmsFemaleColorectal NeoplasmsCEREAL FIBERWhole grain030209 endocrinology & metabolismWhole grains03 medical and health sciencesOAT BETA-GLUCANEnvironmental healthHumansConsumption (economics)030109 nutrition & dieteticsCANCER RISKWhole grain.umbrella reviewbusiness.industryevidenceProstatic NeoplasmsEvidence-based medicineDietmeta-analysisDiabetes Mellitus Type 2GLYCEMIC INDEXObservational studyDOSE-RESPONSE METAANALYSISbusinessFood ScienceInternational Journal of Food Sciences and Nutrition
researchProduct

Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease.

2018

Abstract Pompe disease is an autosomal recessive disorder caused by a deficiency of acid α-glucosidase. In addition to the severe infantile form with cardiac involvement, late-onset variants can affect older children, adolescents (aged >1 year old) or adults. Patients with juvenile (a subgroup of late-onset type) Pompe disease typically do not have cardiac alterations e.g. hypertrophic cardiomyopathy, and the diagnosis is often difficult because it can clinically resemble myriad other neuromuscular disorders. A high level of clinical suspicion is necessary for a timely and accurate diagnosis. We describe 3 interesting cases of patients with juvenile-onset Pompe disease who presented some un…

0301 basic medicineMalePediatricsmedicine.medical_specialtyAdolescentDevelopmental DisabilitiesDisease03 medical and health sciences0302 clinical medicinemedicineJuvenileHumansMuscle SkeletalGenetics (clinical)business.industryGlycogen Storage Disease Type IIGenetic variantsalpha-Glucosidases030104 developmental biologyJuvenile onsetNeurologyPediatrics Perinatology and Child HealthMutationNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular disorders : NMD
researchProduct

Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain.

2018

Growing evidence suggests a link between obesity and neurodegeneration. The purpose of the present study was to explore the neuroprotective potential of glucagon-like peptide-2 (GLP-2) in the brain of high fat diet (HFD)-fed mice. Markers of inflammation and oxidative stress were analysed in the brains of obese mice chronically treated with [Gly2]-GLP-2 (teduglutide), the stable analogue of the GLP-2, and they were compared to age-matched untreated obese and lean animals. Neurodegeneration was examined by TUNEL assay. HFD feeding increased the expression of pro-inflammatory mediators (NF-kB, IL-8, TNF-α, IL-1β and IL-6), glial fibrillary acidic protein (GFAP), index of gliosis and neurodege…

0301 basic medicineMalemedicine.medical_specialtyInflammationmedicine.disease_causeDiet High-FatSettore BIO/09 - FisiologiaNeuroprotectionlcsh:RC321-57103 medical and health sciences0302 clinical medicineNeuroinflammationInternal medicinemedicineGlucagon-Like Peptide 2AnimalsObesityNeurodegenerationlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroinflammationTUNEL assayGlial fibrillary acidic proteinbiologyChemistryNeurodegenerationdigestive oral and skin physiologyBrainmedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyNeuroprotective AgentsNeurologyGliosisOxidative stressAstrocytesbiology.proteinGlucagon-Like Peptide-2 ReceptorOxidative streEncephalitismedicine.symptomInflammation MediatorsGLP-2030217 neurology & neurosurgeryOxidative stresshormones hormone substitutes and hormone antagonistsNeurobiology of disease
researchProduct

Endothelial GLP-1 (Glucagon-Like Peptide 1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension

2019

Supplemental Digital Content is available in the text.

0301 basic medicineMalemedicine.medical_specialtyhypertensionBlotting WesternInflammationBlood Pressure030204 cardiovascular system & hematologyangiotensin IImedicine.disease_causeGlucagon-Like Peptide-1 Receptor1005403 medical and health sciencesMice0302 clinical medicine10030Internal medicinemedicineoxidative stressAnimalsHypoglycemic AgentsReceptor10111Cells CulturedMice KnockoutliraglutideLiraglutidebusiness.industryBasic SciencesType 2 Diabetes MellitusEndothelial CellsAtherosclerosisGlucagon-like peptide-1Angiotensin II3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinology10040inflammationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGRNAmedicine.symptomCardiology and Cardiovascular Medicinebusiness10024Oxidative stressmedicine.drug
researchProduct

Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet

2016

Aim: The purpose of the present study was to investigate the influence of endogenous glucagon-like peptide-2 (GLP-2) on lipid profile in mice fed a standard diet (STD) or a high-fat diet (HFD). Materials and methods: HFD- and age-matched STD mice were injected once a day with GLP-2 (3-33), a GLP-2 receptor (GLP-2R) antagonist, or vehicle for 4 weeks. Results: HFD mice displayed increased intrahepatic lipid concentration and hepatic steatosis and higher plasma concentrations of cholesterol, LDL, AST, and ALT than STD mice. No difference was observed in lipid fecal elimination. In STD mice, the chronic treatment with GLP-2 (3-33) did not affect any parameter, while in HFD mice, it enhanced pl…

0301 basic medicineMalemedicine.medical_specialtyobesityEndogenyBiologyDiet High-FatliverSettore BIO/09 - Fisiologia03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineInsulin resistanceEndocrinologyMetabolic DiseaseslipidInternal medicineinsulin resistancemedicineGlucagon-Like Peptide 2AnimalsReceptormedicine.diagnostic_testCholesterolSettore BIO/16 - Anatomia Umanadigestive oral and skin physiologyAntagonistGeneral Medicinemedicine.diseaseGlucagon-like peptide-2LipidsPeptide FragmentsMice Inbred C57BL030104 developmental biologyEndocrinologychemistrylipids (amino acids peptides and proteins)030211 gastroenterology & hepatologySteatosisLipid profileGLP-2hormones hormone substitutes and hormone antagonists
researchProduct

(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.

2016

OBJECTIVES To determine the effects of a strategy that uses serum (1,3)-β-d-glucan (BDG) results for antifungal treatment of ICU patients at high risk of invasive candidiasis. PATIENTS AND METHODS Adult patients admitted to the ICU from January 2012 to June 2014 were included if they exhibited sepsis at the time of BDG testing and they met Candida score components ≥3. A retrospective analysis of collected data was performed. RESULTS In total, 198 patients were studied. Of 63 BDG-positive patients, 47 with candidaemia and 16 with probable Candida infection, all [31.8% (63/198)] received antifungal therapy. Of 135 BDG-negative patients, 110 [55.5% (110/198)] did not receive antifungal therapy…

0301 basic medicineMicrobiology (medical)AntifungalAdultMalemedicine.medical_specialtyAntifungal AgentsAntigens Fungalbeta-GlucansLetterAdolescentMedicine (all); Pharmacology; Infectious Diseases; Pharmacology (medical)medicine.drug_classCritical Illness030106 microbiologyAntifungal drugSettore MED/17 - MALATTIE INFETTIVESettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAlaw.inventionSepsis03 medical and health sciencesYoung AdultlawInternal medicineSepsismedicineHumansPharmacology (medical)Candidiasis InvasiveMedical prescriptionYoung adultCandidaAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryMedicine (all)Retrospective cohort studyMiddle Agedmedicine.diseaseIntensive care unitSurgeryInfectious DiseasesObservational studyFemaleProteoglycansbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Assessing the biological activity of the glucan phosphatase laforin

2016

Glucan phosphatases are a recently discovered family of enzymes that dephosphorylate either starch or glycogen and are essential for proper starch metabolism in plants and glycogen metabolism in humans. Mutations in the gene encoding the only human glucan phosphatase, laforin, result in the fatal, neurodegenerative, epilepsy known as Lafora disease. Here, we describe phosphatase assays to assess both generic laforin phosphatase activity and laforin's unique glycogen phosphatase activity.

0301 basic medicinePhosphataseLafora diseaseArticleSubstrate SpecificityNitrophenols03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOrganophosphorus CompoundsDual-specificity phosphatasemedicineHumansGlucanEnzyme Assayschemistry.chemical_classificationGlycogenbiologyfood and beveragesBiological activitymedicine.diseaseFluoresceinsProtein Tyrosine Phosphatases Non-Receptor030104 developmental biologyEnzymechemistryBiochemistryLafora Diseasebiology.proteinLaforin030217 neurology & neurosurgeryGlycogen
researchProduct

Quality characteristics and in vitro digestibility study of barley flour enriched ditalini pasta

2016

A ditalini pasta with a mixture of durum wheat and beta-glucan enriched barley flour (BF) (60/40%, w/w) was found to have a final content of 5% beta-glucan (BF-ditalini). Main quality parameters of BF-ditalini, water uptake and starch-protein texture, were comparable with those of 100% durum wheat ditalini (control). After in vitro simulated intestinal digestion, the content of beta-glucan in the post intestinal (PI) supernatant of BF-ditalini processed with its cooking water (soup) was six fold higher than that of pasta asciutta. BF-ditalini soup, but not pasta asciutta, strongly delayed the hydrolysis of the starch, without difference of viscosity between PI supernatant and control. PI su…

0301 basic medicineStarch03 medical and health sciencesHydrolysischemistry.chemical_compound0404 agricultural biotechnologyBarley flour(1/3-1/4) b-glucanSettore BIO/10 - BiochimicaPhenolFunctional food (1/3-1/4) b-glucan Barley flour In vitro digestion Antioxidant capacityFood scienceQuality characteristics030109 nutrition & dieteticsChemistryFunctional foodBarley flourIn vitro digestionfood and beverages04 agricultural and veterinary sciencesIntestinal digestionSettore CHIM/08 - Chimica Farmaceutica040401 food scienceIn vitroAntioxidant capacityAntioxidant capacityFunctional food; (1/3-1/4) b-glucan; Barley flour; In vitro digestion; Antioxidant capacityFood Science
researchProduct